Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vinpocetine in Patients With Parkinsonian Disease
Sponsor: Tanta University
Summary
The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum
Official title: Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease
Key Details
Gender
All
Age Range
50 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-11-10
Completion Date
2027-11-20
Last Updated
2025-12-10
Healthy Volunteers
No
Conditions
Interventions
Levodopa Carbidopa
Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease.
Vinpocetine
VIN, a phosphodiesterase-1 (PDE1) inhibitor, reduces oxidative stress and neuroinflammation and is used clinically for cerebrovascular disease and dementia. In PD, VIN increases dopamine levels, protects dopaminergic neurons, reverses motor impairments, and reduces inflammatory mediators
Locations (1)
Tanta Unuversity
Tanta, Egypt